FDA recently approved once-daily Xigduo XR (dapagliflozin and metformin hydrochloride (HCI) extended-release) for adults with type 2 diabetes, according to AstraZeneca.
FDA recently approved once-daily Xigduo XR (dapagliflozin and metformin hydrochloride (HCI) extended-release) for adults with type 2 diabetes, according to AstraZeneca.
It is approved as an adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both dapagliflozin and metformin is appropriate.
Doctors say type 2 diabetes needs more holistic approach
Xigduo XR is the first once-daily tablet combining a sodium glucose co-transporter 2 (SGLT2) inhibitor and metformin HCI extended-release, a biguanide, approved in the United States.
“The addition of Xigduo XR to our U.S. diabetes portfolio is further evidence of AstraZeneca’s commitment to develop new treatment options for patients with type 2 diabetes,” said Elisabeth Björk, head of cardiovascular & metabolism, global medicines development, AstraZeneca. “The approval of once-daily Xigduo XR provides prescribers and adult patients with another treatment choice, supporting a more [personalized] approach to disease management.”
Xigduo XR removes glucose from the body through the kidneys. Click here to read Xigduo XR dosing instructions.
Psychiatric Pharmacist Helping to Bridge the Care Gap for Patients With Mental Illness
October 24th 2024Nina Vadiei, PharmD, BCPP, a clinical associate professor at UT Austin and a clinical pharmacy specialist in psychiatry at San Antonio State Hospital, discusses her career as a psychiatric pharmacist.